Monday, February 16, 2026 2/16/2026

Tools for Accelerating R&D for Historically Understudied Protein Kinases

Award Number: R44TR001916
ORGANIZATION: NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 02/01/2017
PERIOD OF PERFORMANCE END DATE: 01/31/2020

Group Awards By:

View Award Description

Tools for Accelerating R&D for Historically Understudied Protein Kinases - Protein kinases are central players in almost every aspect of human physiology and serve as critical mediators of signal transduction. The dysfunction of many kinases is implicated in cancer, diabetes, inflammation, and cardiovascular diseases and many are validated targets for therapeutic intervention. The human genome encodes ~518 protein kinases. Yet, the 25 or so marketed protein kinase drugs, target only a small fraction of the human kinome. A greater portion remains unexplored, with very little information available on their role in cell signaling. Chemical tools can play a pivotal role in target discovery and validation. Selective and potent small-molecule kinase inhibitors can be used to address this knowledge gap by pharmacological knockdown of a target protein-kinase in their native environment and probe the effect of inhibition on cell signaling and disease pathology. Our goal is to systematically focus on the vast number of historically understudied kinases, which are currently non-druggable due to lack of mechanistic and functional understanding due to a paucity of reagents and associated assays to gauge selectivity, This gap will be addressed by high-quality chemical probe development, capable of selectively interrogating function of target kinases. During the Phase II period, we will iteratively a) develop low-cost, robust assays using our platform split-luciferase technology for the understudied kinases and, b) develop high- quality chemical probes, which can help deconvolute kinase biology and target discovery. The chemical probe sets developed under this grant will be available as a resource to the research community.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2020 ( Subtotal = $0 )
2020	2018	LUCEOME BIOTECHNOLOGIES, L.L.C.	1665 E. 18TH STREET, SUITE 106	TUCSON	AZ	85719	PIMA	USA	National Center for Advancing Translational Sciences	000	2	9/13/2020	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2018 ( Subtotal = $699,809 )
2018	2018	LUCEOME BIOTECHNOLOGIES, L.L.C.	1665 E. 18TH STREET, SUITE 106	TUCSON	AZ	85719	PIMA	USA	National Center for Advancing Translational Sciences	000	2	1/15/2018	NON-COMPETING CONTINUATION	$699,809
														Subtotal = $699,809

Issue Date FY: 2017 ( Subtotal = $708,631 )
2017	2017	LUCEOME BIOTECHNOLOGIES, L.L.C.	1665 E. 18TH STREET, SUITE 106	TUCSON	AZ	85719	PIMA	USA	National Center for Advancing Translational Sciences	000	1	2/1/2017	NEW	$708,631
														Subtotal = $708,631

Grand Total All Awards = $1,408,440

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Tools for Accelerating R&D for Historically Understudied Protein Kinases

Award Number: R44TR001916

ORGANIZATION: NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 02/01/2017

PERIOD OF PERFORMANCE END DATE: 01/31/2020

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer